University of California
Welcome,         Profile    Billing    Logout  
 183 Trials 
294 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chang, Susan M
SURVIVE, NCT05163080: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Active, not recruiting
2
247
US
SurVaxM
MimiVax, LLC, Translational Drug Development, Merit
Newly Diagnosed Glioblastoma
08/24
08/24
NCT04540107: Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma

Recruiting
1
300
US
Hyperpolarized Carbon C 13 Pyruvate, Hyperpolarized 13C-Pyruvate, Hyperpolarized Pyruvate (13C), Magnetic Resonance Imaging, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Magnetic Resonance Spectroscopic Imaging, 1H- Nuclear Magnetic Resonance Spectroscopic Imaging, 1H-nuclear magnetic resonance spectroscopic imaging, Magnetic Resonance Spectroscopy, MRS, MRS Imaging, MRSI, Proton Magnetic Resonance Spectroscopic Imaging
Susan Chang, GE Healthcare, Sigma-Aldrich, Phillips-Medisize, National Cancer Institute (NCI)
Recurrent World Health Organization (WHO) Grade II Glioma, Recurrent WHO Grade III Glioma, WHO Grade II Glioma, WHO Grade III Glioma
01/27
01/27
Golden, Jeffrey
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Hourglass May 2024 - Aug 2024 : Topline data for IPF
Hourglass Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF
Recruiting
3
576
Canada, US
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
IPF COMFORT, NCT05185089 / 2021-006278-22: Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis

Completed
2
80
Europe, US
Orvepitant Maleate, Placebo
Nerre Therapeutics Ltd., Pharm-Olam International
Cough, Idiopathic Pulmonary Fibrosis
06/24
06/24
NCT05571059: Oral Ifetroban in Patients with Idiopathic Pulmonary Fibrosis (IPF)

Recruiting
2
128
US
Ifetroban Sodium, ifetroban, Placebo
Cumberland Pharmaceuticals
Idiopathic Pulmonary Fibrosis
01/26
01/26
Rosenthal, Philip
NCT06165341: Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

Recruiting
3
50
Europe, Canada, US
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo
Takeda
Alpha1-Antitrypsin Deficiency
08/28
08/28
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Recruiting
3
160
Europe, Canada, US, RoW
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride
Takeda, Takeda Development Center Americas, Inc.
Alpha1-Antitrypsin Deficiency
03/27
03/29
RISE, NCT04729751 / 2020-004628-40: A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).

Completed
2
27
Europe, US, RoW
Maralixibat, Formerly LUM001 and SHP625
Mirum Pharmaceuticals, Inc.
Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome, Cholestatic Liver Disease
12/24
12/24
Ko, Andrew
RESET-RA, NCT04539964: Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis

Active, not recruiting
3
243
US
Implant Procedure, Surgical placement of vagus nerve stimulator inside the neck, Conventional Synthetic DMARD, Background therapy with conventional synthetic DMARD, Active stimulation, Non-active stimulation
SetPoint Medical Corporation
Rheumatoid Arthritis
05/24
10/27
NCT05221320: Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies

Terminated
2
47
US
Ulixertinib, BVD-523, BVD523, Hydroxychloroquine
BioMed Valley Discoveries, Inc
Tumor, Solid, Gastrointestinal Cancer
05/24
07/24
DisTinGuish, NCT04363801: A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Hourglass Oct 2023 - Mar 2024 : Q4'23/Q1'24 - Initial ORR data from DisTinGuish trial for 2L gastric cancer
Oct 2023 - Dec 2023: Initial data from part C of DisTinGuish trial in combination with tislelizumab for 1L gastric cancer
Checkmark Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Nov 2022 - Nov 2022: Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Checkmark ORR, PFS and OS data from DisTinGuish trial in combination with tislelizumab for gastroesophageal junction cancer or gastric cancer
More
Active, not recruiting
2
232
Europe, US, RoW
DKN-01 300mg, DKN-01 600mg, DKN-01 400mg, Tislelizumab 200mg, Tislelizumab 400mg, Oxaliplatin, Capecitabine 1000mg/ m2 BID, Xeloda, Leucovorin Calcium, Folinic acid, Fluorouracil
Leap Therapeutics, Inc., BeiGene
Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer
06/25
12/25
NCT05249101: A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma

Recruiting
1/2
70
US
Ivaltinostat, Capecitabine, Xeloda
CG Pharmaceuticals, Inc
Metastatic Pancreatic Adenocarcinoma
02/26
06/26
RAMP205, NCT05669482: Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

Recruiting
1/2
40
US
avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel, Gemzar, Abraxane
Verastem, Inc.
KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic, Malignant Neoplasm of Pancreas
05/25
12/25
THREAD, NCT03825289: Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer

Recruiting
1
39
US
Hydroxychloroquine, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
University of Utah, Novartis Pharmaceuticals
Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unresectable Pancreatic Carcinoma
01/25
01/26
Young, William B
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

Completed
2
797
NA
ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline
AEON Biopharma, Inc., PPD
Migraine
06/24
08/24
Fong, Lawrence
NCI-2017-01387, NCT02451423: Neoadjuvant Atezolizumab in Localized Bladder Cancer

Completed
2
23
US
Atezolizumab, MPDL3280A
Lawrence Fong, Genentech, Inc., The Bladder Cancer Advocacy Network, Conquer Cancer Foundation, National Cancer Institute (NCI), The V Foundation
Carcinoma, Transitional Cell
03/23
03/23
NCT03248570: Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects

Completed
2
26
US
Pembrolizumab, KEYTRUDA, MK-3475, Chemotherapy
University of California, San Francisco, Merck Sharp & Dohme LLC, National Cancer Institute (NCI)
Castration Resistant Prostatic Cancer, Metastatic Prostate Cancer
09/23
09/23
NCT04064190: Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

Withdrawn
2
48
US
Vactosertib(TEW-7197)/ Durvalumab
MedPacto, Inc., AstraZeneca
Urothelial Carcinoma Recurrent, Advanced Urothelial Carcinoma
12/23
12/24
NCT03007732: Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Active, not recruiting
2
23
US
Pembrolizumab, MK-3475, Keytruda, SD-101, Toll-like receptor 9, Leuprolide acetate, Intermittent androgen deprivation therapy, Abiraterone Acetate, Prednisone, Stereotactic Body Radiation Therapy, SBRT
David Oh, Prostate Cancer Foundation, Merck Sharp & Dohme LLC, TriSalus Life Sciences, Inc.
Prostatic Neoplasms
08/25
08/25
NCT03821246: Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

Recruiting
2
68
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Tocilizumab, Actemra, Etrumadenant, AB928
David Oh, Genentech, Inc.
Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate Cancer
02/25
02/25
NCT05018273: Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors

Completed
1
26
Europe, US
VB10.NEO, Atezolizumab, Tecentriq
Nykode Therapeutics ASA, Genentech, Inc., Vaccibody AS
Solid Tumors, Adult
10/24
10/24
Lee, Andrew K
PREDICT, NCT03448926: The Registry:

Recruiting
N/A
3000
US
Treatment Recommendation Surveys, 7-gene biosignature
PreludeDx, University of South Florida
DCIS
12/25
12/35
NCT04840797: HeartStart HS1 Defibrillator* Event Registry

Recruiting
N/A
1400
US
HeartStart HS1
Philips Clinical & Medical Affairs Global
Sudden Cardiac Arrest
12/27
12/27
NCT05270707: HyperArc Registry Study

Recruiting
N/A
5000
US, RoW
Stereotactic radiosurgery, HyperArc SRS
Varian, a Siemens Healthineers Company
Brain Metastases, CNS Neoplasm, CNS Disorder, Intracranial
12/31
12/31
Wilder-Smith, Petra
NCT00540774: Optical Sensor for Photodynamic Detection of Oral Pathology

Recruiting
N/A
2500
US
detection of oral pathology
University of California, Irvine, National Institute for Biomedical Imaging and Bioengineering (NIBIB), National Institute of Dental and Craniofacial Research (NIDCR), Livionex Inc., Orahealth, National Cancer Institute (NCI)
Mouth Diseases
12/28
12/28
Lu, Ying
FUMANBA-03, NCT06464991: A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM

Recruiting
3
240
RoW
Equecabtagene Autoleucel Injection, FUCASO, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone
Nanjing IASO Biotechnology Co., Ltd.
Multiple Myeloma
08/27
12/30
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease

Recruiting
3
182
RoW
Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Graft-versus-host Disease
10/29
12/30
NCT06300320: A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease

Recruiting
2
40
RoW
TQ05105 tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Graft Versus Host Disease
10/25
04/26
NCT05422066: Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

Hourglass Jan 2023 - Dec 2023 : Market entry for endometrial cancer
Recruiting
2
50
RoW
Selinexor, ATG-010, Xpovio, Rituximab, RiTUXimab Injection, Cyclophosphamide, Cyclophosphamide Injection, Doxorubicin, Doxorubicin Hydrochloride, Vincristine, Vincristine Injection, Prednisone, Prednisone Oral Product
Li Zhiming, Antengene Corporation
DLBCL Germinal Center B-Cell Type
07/25
12/25
NCT05842512: Study of ADI-PEG 20 Versus Placebo in Subjects With NASH

Recruiting
2
40
RoW
ADI-PEG20, Pegargiminase, Placebo
Polaris Group
Nonalcoholic Steatohepatitis (NASH)
12/27
01/28
NCT05528887: Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

Recruiting
1
10
RoW
Autologous CAR-T cells, Fludarabine, Fludara, Cyclophosphamide, Cytoxan
The Affiliated People's Hospital of Ningbo University, UTC Therapeutics Inc.
Relapsed/Refractory Hematological Malignancies, Lymphoma, Myeloma, Leukemia
06/24
06/26
NCT06142175: Relmacabtagene Autoleucel in Patients With LBCL

Recruiting
N/A
200
RoW
Relmacabtagene Autoleucel, JWCAR029
Shanghai Ming Ju Biotechnology Co., Ltd.
Large B-cell Lymphoma
12/24
12/24
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma

Active, not recruiting
N/A
1000
RoW
No Intervention
Takeda
Lymphoma
06/26
06/26
Butowski, Nicholas A
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
SURVIVE, NCT05163080: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Active, not recruiting
2
247
US
SurVaxM
MimiVax, LLC, Translational Drug Development, Merit
Newly Diagnosed Glioblastoma
08/24
08/24
NCT04762069 / 2021-003659-40: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Hourglass Jan 2023 - Jun 2023 : Data from trial for glioblastoma
Hourglass Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults
Active, not recruiting
2
210
Europe, US
Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine
CNS Pharmaceuticals, Inc., Worldwide Clinical Trials
Glioblastoma Multiforme, Adult
12/24
03/25
NCT05503797 / 2022-000627-20: A Study to Assess the Efficacy and Safety of FORE8394 in Participants with Cancer Harboring BRAF Alterations

Recruiting
2
250
Europe, Canada, US, RoW
Plixorafenib, FORE8394, PLX8394, Cobicistat, TYBOST(R)
Fore Biotherapeutics, Fore Biotherapeutics
Cancer Harboring BRAF Alterations
06/25
08/26
ST101-101, NCT04478279 / 2019-004213-13: A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Active, not recruiting
1/2
125
Europe, US
ST101, Temozolomide, Radiation
Sapience Therapeutics
Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer, Glioblastoma Multiforme, GBM, Brain Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Melanoma Recurrent, Prostate Cancer Metastatic, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
12/24
12/25
TNG908-C101, NCT05275478 / 2021-005605-27: Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Active, not recruiting
1/2
192
Europe, US
TNG908
Tango Therapeutics, Inc., Tango Therapeutics, Inc.
Locally Advanced Solid Tumor
04/25
09/25
NCT05370508: A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM

Terminated
1/2
8
US
SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS), Exablate Type 2.0
SonALAsense, Inc.
Recurrent GBM
06/24
07/24
NCT02022644: Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma

Completed
1
18
US
nanoliposomal irinotecan, MM-398, ONIVYDE
University of California, San Francisco, Ipsen, National Cancer Institute (NCI)
High Grade Glioma
12/20
05/23
NCT02924038: A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

Terminated
1
14
US
IMA950, IMA950 peptides, poly-ICLC, Hiltonol, Varlilumab, CDX-1127
Nicholas Butowski, Celldex Therapeutics, National Cancer Institute (NCI)
Glioma, Malignant Glioma, Astrocytoma, Grade II, Oligodendroglioma, Glioma, Astrocytic, Oligoastrocytoma, Mixed
12/22
12/22
FRONTIER, NCT05303467: A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

Active, not recruiting
1
12
US
TheraSphere GBM, TheraSphere™ GBM Y-90 Glass Microspheres (TheraSphere GBM)
Boston Scientific Corporation
Glioblastoma Multiforme, Recurrent Glioblastoma
12/24
06/25
NCT04656535: AB154 Combined with AB122 for Recurrent Glioblastoma

Recruiting
1
46
US
Zimberelimab, Domvanalimab, Placebo
Yale University, National Cancer Institute (NCI), Arcus Biosciences, Inc.
Glioblastoma
02/25
12/25
NCT05557292: RMC-5552 Monotherapy in Adult Subjects with Recurrent Glioblastoma

Recruiting
1
48
US
RMC-5552, mTORC1/4EBP1
Nicholas Butowski, Revolution Medicines, Inc., National Cancer Institute (NCI)
Glioblastoma, Recurrent Glioblastoma
12/25
12/25
Michail, Sonia
NCT03325855: Fecal Microbiota Transplant National Registry

Recruiting
N/A
4000
Canada, US
None - Observational, Observational
American Gastroenterological Association, OpenBiome, University of California, San Diego, Commure, University of Pennsylvania, University of Minnesota, Loyola University Chicago
Fecal Microbiota Transplantation, Clostridium Difficile Infection, Gut Microbiome
08/27
08/27
Dvorak, Christopher
BRIDGE, NCT05787574: A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition

Recruiting
2
39
US
Emapalumab, Fludarabine and Dexamethasone, Stem Cell Transplant
Memorial Sloan Kettering Cancer Center, Sobi, Inc.
Primary Immune Regulatory Disorder, Autoimmune Lymphoproliferative, Immune System Diseases
03/27
03/27
NCT02963064: JSP191 Antibody Targeting Conditioning in SCID Patients

Recruiting
1/2
40
US
Humanized anti-CD117 Monoclonal Antibody (JSP191)
Jasper Therapeutics, Inc.
SCID
06/25
06/28
Clarke, Jennifer
SURVIVE, NCT05163080: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Active, not recruiting
2
247
US
SurVaxM
MimiVax, LLC, Translational Drug Development, Merit
Newly Diagnosed Glioblastoma
08/24
08/24
Okada, Hideho
CA209-8TX, NCT02960230: H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas

Completed
1/2
50
Europe, US
K27M peptide, Nivolumab
Sabine Mueller, MD, PhD, The V Foundation for Cancer Research, Pacific Pediatric Neuro-Oncology Consortium, Bristol-Myers Squibb
Diffuse Intrinsic Pontine Glioma, Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
12/23
12/23
NCT02924038: A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

Terminated
1
14
US
IMA950, IMA950 peptides, poly-ICLC, Hiltonol, Varlilumab, CDX-1127
Nicholas Butowski, Celldex Therapeutics, National Cancer Institute (NCI)
Glioma, Malignant Glioma, Astrocytoma, Grade II, Oligodendroglioma, Glioma, Astrocytic, Oligoastrocytoma, Mixed
12/22
12/22
Conte, Michael
NCT04267640: Study of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects With Peripheral Ischemic Ulcers

Recruiting
2
60
US
AMG0001, HGF plasmid, Collategene, beperminogene perplasmid, Placebo
AnGes USA, Inc.
Peripheral Artery Disease, Ischaemic Ulcer of Lower Leg Due to Atherosclerotic Disease, Chronic Limb Threatening Ischemia, Ischemic Ulcer of Foot
07/22
01/23
EnEPC-CLI, NCT02805023: BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI)

Recruiting
1/2
50
US, RoW
BGC101 (autologous EnEPC preparation), Control medium
BioGenCell Ltd., Laniado Hospital, Rabin Medical Center
Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease
12/27
12/27
NCT04514861: Monitoring Local Tissue Oxygen Changes Using the Wireless Lumee Oxygen Platform in Correlation to TcPO2

Recruiting
N/A
53
US
Wireless Lumee Oxygen Platform
Profusa, Inc., National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
Peripheral Artery Disease
12/21
05/22
PATENT, NCT06264843: Peripheral Bypass Trial for Completion Control

Recruiting
N/A
450
US
MiraQ with Transit-Time Flow Measurement (TTFM) and L15 High Frequency Ultrasound (HFUS) probes
Medistim ASA
Chronic Limb-Threatening Ischemia
12/27
12/27
NCT05313165: PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

Recruiting
N/A
100
US
LimFlow Stent Graft System
LimFlow, Inc.
Critical Limb Ischemia, Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease
05/27
05/27
Mahadevan, Vaikom
NCT02661451: Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)

Active, not recruiting
N/A
178
Europe, Canada, US
SAPIEN 3 THV, Optimal Heart Failure Therapy
Cardiovascular Research Foundation, New York, Cardialysis BV, Avania
Aortic Valve Stenosis
02/23
02/25
SUMMIT, NCT03433274: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation

Recruiting
N/A
958
Canada, US
Tendyne Mitral Valve System, MitraClip System
Abbott Medical Devices
Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease
05/24
06/28
NCT03309332: AMPLATZER PFO Occluder Post Approval Study

Active, not recruiting
N/A
1214
Europe, Canada, US
AMPLATZER™ PFO Occluder
Abbott Medical Devices
Stroke, Patent Foramen Ovale
02/30
02/30
REDUCE PAS, NCT03821129: GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study

Recruiting
N/A
636
US
PFO closure with GORE® CARDIOFORM Septal Occluder
W.L.Gore & Associates
Stroke, PFO - Patent Foramen Ovale
12/26
12/29
NCT03142152: The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR

Recruiting
N/A
300
Europe, US
Carillon Mitral Contour System, Carillon, Percutaneous mitral valve repair, Guideline Directed Heart Failure Medication
Cardiac Dimensions, Inc.
Functional Mitral Regurgitation, Heart Failure, Mitral Valve Insufficiency, Heart Diseases, Cardiovascular Diseases, Heart Valve Diseases
12/26
12/30
Klein, Liviu
DETECT-HF, NCT06378632: AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM

Recruiting
N/A
500
Europe, US, RoW
Hearo App
Cordio Medical
Heart Failure
01/25
03/25
Rebalance-HF, NCT04592445: Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF

Recruiting
N/A
80
US
Satera GSN Ablation, Sham Control
Axon Therapies, Inc.
Heart Failure With Preserved Ejection Fraction
04/22
03/23
NCT04223934: Tailored Drug Titration Using Artificial Intelligence

Completed
N/A
164
US
optima4BP
Optima Integrated Health, University of California, San Francisco
Hypertension
12/22
06/23
NCT05206422: DORAYA-HF Early Feasibility Study

Recruiting
N/A
30
US
Doraya Catheter
Revamp Medical Inc.
Acute Decompensated Heart Failure
10/25
12/25
CorCinch-HF, NCT04331769: Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF): the CORCINCH-HF Study

Recruiting
N/A
400
Europe, US, RoW
AccuCinch Ventricular Restoration System, Guideline-Directed Medical Therapy
Ancora Heart, Inc.
Heart Failure with Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
12/26
12/30
REVERSE-HF, NCT05318105: Ultrafiltration Versus IV Diuretics in Worsening Heart Failure

Recruiting
N/A
372
US
Aquadex Smartflow® System, IV Loop Diuretics
Nuwellis, Inc.
Heart Failure (for Example, Fluid Overload)
07/25
10/25
NCT03523416: Early Feasibility Study - Edwards APTURE Transcatheter Shunt System

Active, not recruiting
N/A
71
US
Transcatheter Atrial Shunt System
Edwards Lifesciences
Heart Failure
12/23
11/28
NCT05047068: OCS Heart Perfusion Post-Approval Registry

Active, not recruiting
N/A
350
US
OCS Heart System
TransMedics
Transplant
12/25
12/29
ReDS-HF, NCT03586336: Remote Dielectric Sensing (ReDS) Assisted Diuresis in Acute Decompensated Heart Failure

Recruiting
N/A
100
US
ReDS-Guided, Usual Care
University of California, San Francisco, Sensible Medical Innovations Ltd.
Heart Failure; With Decompensation
12/25
12/25
rēST Study, NCT03884660: Remedē System Therapy Study

Recruiting
N/A
500
Europe, US
remede System
Respicardia, Inc.
Central Sleep Apnea
06/27
06/32
OHP-II, NCT05915299: US National OCS Heart Perfusion (OHP) Registry

Recruiting
N/A
100000
US
OCS Heart
TransMedics
Heart Transplant
08/29
08/33
Wahlstrom, Justin
EBVision, NCT04554914 / 2020-000177-25: A Study to Evaluate Tabelecleucel in Participants with Epstein-barr Virus-associated Diseases

Hourglass Jan 2023 - Dec 2023 : From P2 trial for Epstein-Barr virus-associated sarcoma
Recruiting
2
190
Europe, US
Tabelecleucel, tab-cel®, ATA129, EBV-CTLs
Atara Biotherapeutics
Epstein-Barr Virus (EBV)-associated Diseases, EBV+ Lymphoproliferative Disease with Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease with Acquired (non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma
06/27
05/29
Chi, Thomas
AEROLITH, NCT04563039: Acoustic Enhancer Research on Laser Lithotripsy

Active, not recruiting
N/A
196
US
Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer, Standard Ureteroscopic Laser Lithotripsy
Applaud Medical, Inc.
Urinary Stones
06/23
08/24
NCT03811171: Break Wave(TM) Extracorporeal Lithotripter First-in-Human Study

Active, not recruiting
N/A
30
Canada, US
Break Wave extracorporeal lithotripsy
SonoMotion
Renal Calculi, Urinary Calculi
01/24
03/25
Taylor, Jennie
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
01/26
01/28
Chang, Edward
NCT06422923: A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

Recruiting
1/2
10
US
NRTX-1001, GABA-secreting interneurons
Neurona Therapeutics
Epilepsy, Temporal Lobe
07/26
07/40
MTLE, NCT05135091: FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy

Recruiting
1/2
40
US
NRTX-1001, GABA-secreting interneurons, Sham Comparator
Neurona Therapeutics, California Institute for Regenerative Medicine (CIRM)
Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis
05/25
05/26
NCT04606030: LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)

Recruiting
N/A
60
US
BioBridge® Collagen Matrix, Vascularized Lymph Node Transfer (VLNT)
Fibralign Corporation, University of Chicago
Lymphedema, Edema
12/23
02/24
Daras, Mariza
SURVIVE, NCT05163080: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Active, not recruiting
2
247
US
SurVaxM
MimiVax, LLC, Translational Drug Development, Merit
Newly Diagnosed Glioblastoma
08/24
08/24
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
01/26
01/28
NCT03423628: A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Jan 2024 - Dec 2024: Data from trial in combination with radiation therapy for brain metastases
Recruiting
1
180
Europe, Japan, US
Radiation Therapy, Radiotherapy, Radiation treatment, RT, AZD1390, ATM inhibitor
AstraZeneca
Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)
09/26
09/26
Simon, Marc
ARTISAN, NCT05203510: A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

Recruiting
4
50
US
Parenteral Treprostinil, Remodulin, Oral Treprostinil, Orenitram
United Therapeutics, Lung Biotechnology PBC
Pulmonary Arterial Hypertension
12/25
12/27
IMPAHCT-FUL, NCT05557942 / 2021-006864-25: Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension

Terminated
3
186
Europe, Canada, US, RoW
AV-101
Aerovate Therapeutics, Aerovate Therapeutics Inc
Pulmonary Arterial Hypertension
08/24
08/24
NCT05983250: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

Recruiting
3
152
Canada, US
TNX-103, Placebo
Tenax Therapeutics, Inc., Medpace, Inc., Northwestern University
Pulmonary Hypertension
03/27
07/27
IMPAHCT, NCT05036135 / 2021-001910-13: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

Terminated
2/3
202
Europe, Canada, US, RoW
AV-101, Placebo
Aerovate Therapeutics, Aerovate Therapeutics, Inc.
Pulmonary Arterial Hypertension
08/24
08/24
RELIEVE-PAH, NCT03838445: Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension

Recruiting
N/A
20
Canada, US, RoW
V-Wave Interatrial Shunt
V-Wave Ltd
Pulmonary Arterial Hypertension
06/24
12/26
Horn, Biljana
NCT05322850: Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)

Recruiting
1/2
40
US
Orca-Q
University of Florida, Orca Biosystems, Inc., Florida Department of Health
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia, Chronic Myeloid Leukemia in Myeloid Blast Crisis, Chronic Myeloid Leukemia in Lymphoid Blast Crisis (Diagnosis), Chronic Myeloid Leukemia - Accelerated Phase
09/26
09/27
Kapoor, Yuvraaj
NCT05308472: Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants with EPP

Completed
2
75
US
DISC-1459, Bitopertin, RO4917838, Placebo
Disc Medicine, Inc
Erythropoietic Protoporphyria
02/24
08/24
Wong, Sandy
NCT04549363: Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin

Terminated
3
16
US
Belantamab mafodotin
GlaxoSmithKline
Multiple Myeloma
11/22
11/22
ALTITUDE, NCT05486481: Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14)

Recruiting
1/2
46
US
Venetoclax, Venclexta, Dexamethasone, Ozurdex, Daratumumab, Darzalex, Daratumumab SC, Cyclin D1 gene (CCDN1) /immunoglobulin heavy chain (IGH) fluorescence in situ hybridization (FISH) assay
Alfred Chung, MD, Janssen Pharmaceuticals, AbbVie
AL Amyloidosis, Light Chain (AL) Amyloidosis, Systemic Light Chain Disease
12/27
12/27
NCT04754945: Isatuximab As Upfront Therapy for the Treatment of High Risk AL Amyloidosis

Active, not recruiting
1
11
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Isatuximab, Hu 38SB19, Isatuximab-irfc, SAR 650984, SAR650984, Sarclisa
Emory University, Sanofi, National Cancer Institute (NCI)
AL Amyloidosis
07/25
07/26
Burgoyne, Adam M
ROWAN, NCT05063565 / 2021-001907-33: TheraSphere With Durvalumab and Tremelimumab for HCC

Recruiting
2
100
Europe, US
TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy
Boston Scientific Corporation, Biocompatibles UK Ltd
Hepatocellular Carcinoma
06/27
06/27
NCT05733598: Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Recruiting
2
30
US
RP2, Bevacizumab, Avastin, Atezolizumab, Tecentriq
Replimune Inc., Roche Pharma AG
Hepatocellular Carcinoma
12/27
07/28
NCT03715933: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting
1
321
Europe, US
INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide
Inhibrx Biosciences, Inc
Colorectal Adenocarcinoma, Ewing Sarcoma
06/26
12/26
Vogrinec, Ute
SURVIVE, NCT05163080: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Active, not recruiting
2
247
US
SurVaxM
MimiVax, LLC, Translational Drug Development, Merit
Newly Diagnosed Glioblastoma
08/24
08/24
Rabbitt, Jane
SURVIVE, NCT05163080: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Active, not recruiting
2
247
US
SurVaxM
MimiVax, LLC, Translational Drug Development, Merit
Newly Diagnosed Glioblastoma
08/24
08/24
Elmariah, Sammy
NCT05646381: A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

Recruiting
2
502
Europe, Canada, US, RoW
Pelacarsen (TQJ230) 80mg, TQJ230, Matching placebo, Placebo
Novartis Pharmaceuticals
Aortic Stenosis
01/29
01/29
HALT, NCT04552275: The Biomarker Study

Recruiting
1
300
US
Proteomics Analysis
Massachusetts General Hospital, Medtronic, Catholic Medical Center, Minneapolis Heart Institute
Aortic Stenosis, Hypo-attenuated Leaflet Thickening, Bioprosthetic Valve Degeneration
06/30
06/35
 

Download Options